O Heikinheimo

Summary

Affiliation: University of Helsinki
Country: Finland

Publications

  1. ncbi request reprint The levonorgestrel-releasing intrauterine system (LNG-IUS) in HIV-infected women--effects on bleeding patterns, ovarian function and genital shedding of HIV
    Oskari Heikinheimo
    Department of Obstetrics and Gynaecology, University of Helsinki, Finland
    Hum Reprod 21:2857-61. 2006
  2. ncbi request reprint The molecular mechanisms of oocyte maturation and early embryonic development are unveiling new insights into reproductive medicine
    O Heikinheimo
    Department of Biomedicine, University of Helsinki, Finland
    Mol Hum Reprod 4:745-56. 1998
  3. ncbi request reprint Advanced cervical pregnancy: uterus-sparing therapy initiated with a combination of methotrexate and mifepristone followed by evacuation and local hemostatic measures
    Oskari Heikinheimo
    Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland
    Acta Obstet Gynecol Scand 83:211-3. 2004
  4. ncbi request reprint Mifepristone may inhibit the midcycle gonadotropin surge at both ovarian and pituitary sites of action
    Oskari Heikinheimo
    Department of Obstetrics and Gynecology, University of Helsinki, Helsinki, Finland
    Fertil Steril 84:1545-6. 2005
  5. ncbi request reprint The pharmacokinetics of mifepristone in humans reveal insights into differential mechanisms of antiprogestin action
    Oskari Heikinheimo
    Department of Obstetrics and Gynecology, University of Helsinki, P O Box 140, SF 00029, HUS, Helsinki, Finland
    Contraception 68:421-6. 2003
  6. ncbi request reprint Intrauterine release of progesterone antagonist ZK230211 is feasible and results in novel endometrial effects: a pilot study
    Oskari Heikinheimo
    Department of Obstetrics and Gynaecology, University of Helsinki, PO Box 140, SF 00029 HUS, Helsinki, Finland
    Hum Reprod 22:2515-22. 2007
  7. ncbi request reprint Termination of early pregnancy using flexible, low-dose mifepristone-misoprostol regimens
    Oskari Heikinheimo
    Department of Obstetrics and Gynecology, University of Helsinki, PO Box 140, SF 00029 Helsinki, Finland
    Contraception 76:456-60. 2007
  8. ncbi request reprint Alterations in sex steroids and gonadotropins in post-menopausal women subsequent to long-term mifepristone administration
    O Heikinheimo
    Steroid Research Laboratory, Department of Biomedicine, University of Helsinki, Helsinki, Finland
    Steroids 65:831-6. 2000
  9. doi request reprint Age, parity, history of abortion and contraceptive choices affect the risk of repeat abortion
    Oskari Heikinheimo
    Department of Obstetrics and Gynecology, University of Helsinki, SF 00029 Helsinki, Finland
    Contraception 78:149-54. 2008
  10. ncbi request reprint Clinical pharmacokinetics of mifepristone
    O Heikinheimo
    Department of Biomedicine, University of Helsinki, Finland
    Clin Pharmacokinet 33:7-17. 1997

Collaborators

Detail Information

Publications48

  1. ncbi request reprint The levonorgestrel-releasing intrauterine system (LNG-IUS) in HIV-infected women--effects on bleeding patterns, ovarian function and genital shedding of HIV
    Oskari Heikinheimo
    Department of Obstetrics and Gynaecology, University of Helsinki, Finland
    Hum Reprod 21:2857-61. 2006
    ..The levonorgestrel-releasing intrauterine system (LNG-IUS) is a highly effective contraceptive with additional health benefits. The objective of this study was to evaluate the effects of the LNG-IUS among HIV-infected women...
  2. ncbi request reprint The molecular mechanisms of oocyte maturation and early embryonic development are unveiling new insights into reproductive medicine
    O Heikinheimo
    Department of Biomedicine, University of Helsinki, Finland
    Mol Hum Reprod 4:745-56. 1998
    ..We acknowledge that most of the data presented comes from species other than human, therefore at present the full biological role of the proposed regulatory pathways and control mechanisms for human biology remains speculative...
  3. ncbi request reprint Advanced cervical pregnancy: uterus-sparing therapy initiated with a combination of methotrexate and mifepristone followed by evacuation and local hemostatic measures
    Oskari Heikinheimo
    Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland
    Acta Obstet Gynecol Scand 83:211-3. 2004
  4. ncbi request reprint Mifepristone may inhibit the midcycle gonadotropin surge at both ovarian and pituitary sites of action
    Oskari Heikinheimo
    Department of Obstetrics and Gynecology, University of Helsinki, Helsinki, Finland
    Fertil Steril 84:1545-6. 2005
    ..In the current work, late-follicular phase administration of mifepristone resulted in decrease in both circulating FSH and inhibin B, suggesting both central and ovarian sites of action...
  5. ncbi request reprint The pharmacokinetics of mifepristone in humans reveal insights into differential mechanisms of antiprogestin action
    Oskari Heikinheimo
    Department of Obstetrics and Gynecology, University of Helsinki, P O Box 140, SF 00029, HUS, Helsinki, Finland
    Contraception 68:421-6. 2003
    ..It remains to be seen whether the newly synthesized, more selective antiprogestins will prove more efficacious in the clinical arena...
  6. ncbi request reprint Intrauterine release of progesterone antagonist ZK230211 is feasible and results in novel endometrial effects: a pilot study
    Oskari Heikinheimo
    Department of Obstetrics and Gynaecology, University of Helsinki, PO Box 140, SF 00029 HUS, Helsinki, Finland
    Hum Reprod 22:2515-22. 2007
    ..We compared the effects of intrauterine release of a highly specific PA, ZK230211, to those of a progestin using the levonorgestrel-releasing intrauterine system (LNG-IUS)...
  7. ncbi request reprint Termination of early pregnancy using flexible, low-dose mifepristone-misoprostol regimens
    Oskari Heikinheimo
    Department of Obstetrics and Gynecology, University of Helsinki, PO Box 140, SF 00029 Helsinki, Finland
    Contraception 76:456-60. 2007
    ..We examined the effect of a change in protocol from a fixed mifepristone-misoprostol interval to a flexible one on the efficacy and uptake of medical abortion. In addition, risk factors of incomplete abortions were evaluated...
  8. ncbi request reprint Alterations in sex steroids and gonadotropins in post-menopausal women subsequent to long-term mifepristone administration
    O Heikinheimo
    Steroid Research Laboratory, Department of Biomedicine, University of Helsinki, Helsinki, Finland
    Steroids 65:831-6. 2000
    ..However, the lack of change in SHBG and the low E(2) levels suggest that enhanced systemic estrogen effects are unlikely during long-term mifepristone treatment...
  9. doi request reprint Age, parity, history of abortion and contraceptive choices affect the risk of repeat abortion
    Oskari Heikinheimo
    Department of Obstetrics and Gynecology, University of Helsinki, SF 00029 Helsinki, Finland
    Contraception 78:149-54. 2008
    ..However, risk factors as regards repeat abortion are poorly understood. We characterized risk factors related to sociodemographic characteristics, history of abortion and post-abortal contraception...
  10. ncbi request reprint Clinical pharmacokinetics of mifepristone
    O Heikinheimo
    Department of Biomedicine, University of Helsinki, Finland
    Clin Pharmacokinet 33:7-17. 1997
    ..However, it is hoped that the eventual introduction of new antiprogesterone molecules by several manufacturers will enhance the availability of this important class of new drugs...
  11. pmc Contraception and HIV infection in women
    Oskari Heikinheimo
    Department of Obstetrics and Gynaecology, University of Helsinki, Finland
    Hum Reprod Update 15:165-76. 2009
    ..This review aims to show the effect of contraceptive choices on risk of HIV and on the course of disease in women with HIV...
  12. doi request reprint Can the outcome of the next pregnancy be predicted at the time of induced abortion?
    Oskari Heikinheimo
    Department of Obstetrics and Gynaecology, University of Helsinki, PO Box 140, SF 00029, HUS, Finland
    Hum Reprod 24:820-6. 2009
    ..Factors predicting the outcome of the next pregnancy following termination of pregnancy (TOP) are poorly known...
  13. doi request reprint The levonorgestrel-releasing intrauterine system in human immunodeficiency virus-infected women: a 5-year follow-up study
    Oskari Heikinheimo
    Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland
    Am J Obstet Gynecol 204:126.e1-4. 2011
    ..We sought to assess the effects of long-term use and safety of the levonorgestrel-releasing (LNG)-intrauterine system (IUS) among human immunodeficiency virus (HIV)-infected women in comparison with HIV-infected women not using the device...
  14. ncbi request reprint Effect of antiprogesterone mifepristone followed by misoprostol on circulating leptin in early pregnancy
    Helena Honkanen
    Department of Obstetrics and Gynecology, University of Helsinki, SF 00029 HUS, Helsinki, Finland
    Acta Obstet Gynecol Scand 84:134-9. 2005
    ....
  15. doi request reprint Frequency and risk factors for repeat abortions after surgical compared with medical termination of pregnancy
    Maarit Niinimäki
    Department of Obstetrics and Gynecology, University Hospital of Oulu, Oulu, Finland
    Obstet Gynecol 113:845-52. 2009
    ..To compare the frequency and risk factors for repeat abortions after surgical compared with medical termination of pregnancy...
  16. doi request reprint Medical versus surgical termination of pregnancy in primigravid women-is the next delivery differently at risk? A population-based register study
    J Mannisto
    Department of Obstetrics and Gynaecology, University Hospital of Oulu, Oulu, Finland
    BJOG 120:331-7. 2013
    ..To compare the effect of medical versus surgical termination of pregnancy (TOP), performed in primigravid women, on subsequent delivery...
  17. ncbi request reprint Contraception with subdermal implants releasing the progestin ST-1435: a dose-finding study
    M Haukkamaa
    Department of Medical Chemistry, University of Helsinki, Finland
    Contraception 45:49-55. 1992
    ..This method, using a single 4 cm subcutaneous implant releasing the progestin ST-1435 with a life-time of two years, represents a promising alternative for inhibition of ovulation and contraception...
  18. ncbi request reprint The progestin ST 1435--rapid metabolism in man
    O Heikinheimo
    Department of Medical Chemistry, University of Helsinki, Finland
    Contraception 50:275-89. 1994
    ..However, the rapid metabolism seen after oral intake can be successfully circumvented by sustained parenteral administration of ST 1435...
  19. ncbi request reprint A contraceptive vaginal ring releasing ethinyl estradiol and the progestin ST-1435: bleeding control, serum steroid concentrations, serum lipids and serum chemistry
    M Laurikka-Routti
    Department of Medical Chemistry, University of Helsinki, Finland
    Contraception 42:111-20. 1990
    ..This contraceptive vaginal ring presents a good method of contraception, showing good bleeding control and no harmful metabolic effects...
  20. ncbi request reprint Transdermal absorption of the progestin ST-1435: therapeutic serum steroid concentrations and high excretion of the steroid in saliva
    M Haukkamaa
    Department of Medical Chemistry, University of Helsinki, Finland
    Contraception 44:269-76. 1991
    ..However, the concentrations of serum and salivary ST-1435 were not directly correlated in different individuals. Transdermal application of ST-1435 might offer a good alternative for systemic progestin treatment...
  21. ncbi request reprint The learning curve is rapid in medical termination of pregnancy--first-year results from the Helsinki area
    Satu Suhonen
    Women s Hospital, Department of Obstetrics and Gynecology, University of Helsinki, PO Box 140, FIN 00029, Helsinki, Finland
    Contraception 67:223-7. 2003
    ..We conclude that the learning curve in medical termination of pregnancy is rapid, and results comparable to those in centers with extensive experience with the method can be reached within the first year...
  22. ncbi request reprint Experience with the levonorgestrel-releasing intrauterine system among HIV-infected women
    Päivi Lehtovirta
    Department of Obstetrics and Gynecology, University of Helsinki, SF 00029 Helsinki, Finland
    Contraception 75:37-9. 2007
    ..Yet, little is known about LNG-IUS use in HIV-infected women...
  23. ncbi request reprint The kinetics of serum hCG and progesterone in response to oral and vaginal administration of misoprostol during medical termination of early pregnancy
    Helena Honkanen
    Department of Obstetrics and Gynaecology, Helsinki University Central Hospital, Helsinki and Department of Biomedicine, University of Helsinki, Helsinki, Finland
    Hum Reprod 17:2315-9. 2002
    ..The effect of prolonged misoprostol administration was also examined...
  24. doi request reprint Young age and termination of pregnancy during the second trimester are risk factors for repeat second-trimester abortion
    Maarit J Mentula
    Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland
    Am J Obstet Gynecol 203:107.e1-7. 2010
    ..The objective of the study was to characterize women undergoing a termination of pregnancy (TOP) during the second trimester and to evaluate the risk factors and timing of repeat TOP...
  25. ncbi request reprint Misoprostol-only versus mifepristone plus misoprostol in induction of labor following intrauterine fetal death
    Wilma Väyrynen
    Department of Obstetrics and Gynecology, University of Helsinki, Finland
    Acta Obstet Gynecol Scand 86:701-5. 2007
    ..Both misoprostol-alone and a combination of mifepristone plus misoprostol have been used in induction of labor in cases of intrauterine fetal death (IUFD)...
  26. ncbi request reprint One- and 2-day mifepristone-misoprostol intervals are both effective in medical termination of second-trimester pregnancy
    Oskari Heikinheimo
    Women s Hospital, Department of Obstetrics and Gynecology, University of Helsinki, Helsinki, Finland
    Reprod Biomed Online 8:236-9. 2004
    ..001), in the 1- and 2-day interval groups respectively. Thus both 1- and 2-day mifepristone-misoprostol intervals are valuable in termination of second-trimester pregnancy...
  27. ncbi request reprint Pregnancy outcome among HIV-infected women in the Helsinki metropolitan area
    Päivi Lehtovirta
    Department of Obstetrics and Gynecology, University of Helsinki, Helsinki, Finland
    Acta Obstet Gynecol Scand 84:945-50. 2005
    ..The incidence of HIV infection has remained low in Finland. Universal antenatal screening has been offered to all pregnant women since 1998...
  28. doi request reprint Double-blind, randomized, placebo-controlled study on the effect of misoprostol on ease of consecutive insertion of the levonorgestrel-releasing intrauterine system
    Oskari Heikinheimo
    Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland
    Contraception 81:481-6. 2010
    ..Misoprostol has been studied intensively to produce cervical dilatation. To date, no studies have evaluated the effectiveness, safety or acceptability of this treatment for repeat intrauterine device insertions...
  29. doi request reprint Trends in teenage termination of pregnancy and its risk factors: a population-based study in Finland, 1987-2009
    S Leppälahti
    Department of Obstetrics and Gynaecology, Katiloopisto Hospital, University of Helsinki and Helsinki University Central Hospital, PO Box 610, 00029 HUS, Helsinki, Finland
    Hum Reprod 27:2829-36. 2012
    ..What are the current trends in teenage termination of pregnancy (TOP) and its risk factors?..
  30. ncbi request reprint Mifepristone: a potential contraceptive
    O Heikinheimo
    University of Helsinki, Finland
    Clin Obstet Gynecol 39:461-8. 1996
    ....
  31. doi request reprint Predictors of bleeding and user satisfaction during consecutive use of the levonorgestrel-releasing intrauterine system
    O Heikinheimo
    Department of Obstetrics and Gynaecology, Helsinki University Central Hospital, PO Box 610, 00029 HUS Helsinki, Finland
    Hum Reprod 25:1423-7. 2010
    ..The objective of this study was to analyse the possible factors which may predict the bleeding pattern during the first year of use of a second LNG-IUS...
  32. ncbi request reprint Late follicular phase administration of mifepristone suppresses circulating leptin and FSH - mechanism(s) of action in emergency contraception?
    Riikka Leminen
    Department of Obstetrics and Gynecology, University of Helsinki, Helsinki, Finland
    Eur J Endocrinol 152:411-8. 2005
    ..We studied the endocrine actions of 10 mg mifepristone administered orally as a single dose to eight healthy volunteers (aged 20-45 years) during the late follicular phase...
  33. doi request reprint Risk factors, diagnosis and prognosis of cervical intraepithelial neoplasia among HIV-infected women
    Päivi Lehtovirta
    Department of Obstetrics and Gynaecology, University of Helsinki, PO Box 140, SF00029, Helsinki, Finland
    Int J STD AIDS 19:37-41. 2008
    ..However, the patients with and without CIN could not be distinguished on the basis of previously described risk factors. Regular follow-up by means of Pap smears is warranted in all HIV-infected women...
  34. doi request reprint Hormonal contraception and mental health: results of a population-based study
    E Toffol
    Department of Mental Health and Substance Abuse Services, National Institute for Health and Welfare THL, Helsinki, Finland
    Hum Reprod 26:3085-93. 2011
    ..The aim of this study was to analyse the association between the use of OCs and the LNG-IUS and psychological well-being and psychopathology...
  35. ncbi request reprint Parenteral administration of progestin Nestorone to lactating cynomolgus monkeys: an ideal hormonal contraceptive at lactation?
    O Heikinheimo
    Steroid Research Laboratory, Institute of Biomedicine, Department of Obstetrics and Gynecology, University of Helsinki, Finland
    Hum Reprod 14:1993-7. 1999
    ..These data confirm that NES in milk is rapidly metabolized by the suckling infant. Therefore, NES appears to be an ideal hormonal contraceptive for use during lactation...
  36. doi request reprint Oestrogen receptors and small nuclear ring finger protein 4 (RNF4) in malignant ovarian germ cell tumours
    Jonna Salonen
    Paediatric Research Centre, Children s Hospital, Helsinki, Finland
    Mol Cell Endocrinol 307:205-10. 2009
    ..Neither E2 nor ICI 182,780 had an effect on the proliferation of NCC-IT cells as assessed by flow cytometric analysis. Our results suggest that oestrogen signalling has a role in malignant ovarian germ cell tumours...
  37. ncbi request reprint Mifepristone as treatment of recurrent progesterone receptor-positive uterine leiomyosarcoma
    Riitta Koivisto-Korander
    Department of Obstetrics and Gynecology, University of Helsinki, Finland
    Obstet Gynecol 109:512-4. 2007
    ..Leiomyomata and uterine leiomyosarcomas share some common features, and they both often express progesterone receptors. Thus, treatment of uterine leiomyosarcomas with antiprogestins has been suggested...
  38. doi request reprint Immediate complications after medical compared with surgical termination of pregnancy
    Maarit Niinimäki
    Department of Obstetrics and Gynecology, Oulu University Hospital, Oulu, Finland
    Obstet Gynecol 114:795-804. 2009
    ..To estimate the immediate adverse events and safety of medical compared with surgical abortion using high-quality registry data...
  39. ncbi request reprint Prevalence and risk factors of squamous intraepithelial lesions of the cervix among HIV-infected women - a long-term follow-up study in a low-prevalence population
    Päivi Lehtovirta
    Department of Obstetrics and Gynaecology, University of Helsinki, Finland
    Int J STD AIDS 17:831-4. 2006
    ..04) as well as in women displaying high initial HIV viral load (P = 0.01). Our results from a low HIV-incidence population re-emphasize the importance of guidelines for cytologic screening of HIV-seropositive women...
  40. ncbi request reprint Pharmacokinetics of 10 mg of mifepristone
    Riikka Leminen
    Department of Obstetrics and Gynecology, University of Helsinki, P O Box 140, SF 00029, HUS, Helsinki, Finland
    Contraception 68:427-9. 2003
    ..9 days. The pharmacokinetic data on 10 mg mifepristone are in line with previous pharmacokinetic and clinical data, and encourage further development of the 10-mg dose in emergency contraception...
  41. doi request reprint Rectovaginal endometriosis-characteristics of operative treatment and factors predicting bowel resection
    Satu Tarjanne
    Department of Obstetrics and Gynecology, University of Helsinki, Finland
    J Minim Invasive Gynecol 16:302-6. 2009
    ..The purpose of this study was to characterize operative treatment of patients with rectovaginal endometriosis (RVE), with special emphasis on factors predicting bowel resection...
  42. ncbi request reprint Termination of pregnancy with mifepristone and prostaglandin suppresses transiently circulating glucocorticoid bioactivity
    Oskari Heikinheimo
    Department of Obstetrics and Gynecology and Institute of Biomedicine, University of Helsinki and Helsinki University Central Hospital, FIN 00014 Helsinki, Finland
    J Clin Endocrinol Metab 88:323-6. 2003
    ..We conclude that 200 mg mifepristone elicits a significant suppression of serum GBA, to one third of the pretreatment value, despite the compensatory increase in the serum cortisol concentration...
  43. ncbi request reprint Changes in vaginal morphology, steroid receptor and natural antimicrobial content following treatment with low-dose mifepristone
    Nitish Narvekar
    Contraceptive Development Network, Centre for Reproductive Biology, University of Edinburgh, The Queen s Medical Research Institute, 47 Little France Crescent, EH16 4TJ Edinburgh, UK
    Contraception 75:271-80. 2007
    ..We investigate the effects of mifepristone on vaginal thickness, steroid receptor and natural antimicrobial content and pharmacokinetics of mifepristone...
  44. ncbi request reprint [Is monthly menstruation necessary?]
    Oskari Heikinheimo
    HYKS n naistenklinikka, HUS
    Duodecim 121:245-6. 2005
  45. ncbi request reprint [Estrogens, progesterones and the mammary gland]
    Oskari Heikinheimo
    HYKS in naistenklinikka, HUS
    Duodecim 121:525-32. 2005
  46. ncbi request reprint [Pregnancy and labor of a HIV-positive woman]
    Oskari Heikinheimo
    HYKS n naistenklinikka PL 140, 00029 HUS
    Duodecim 118:1405-9. 2002
  47. ncbi request reprint Long-cycle combined contraception: less bleeding and increased subject satisfaction
    Oskari Heikinheimo
    Acta Obstet Gynecol Scand 85:517-8. 2006
  48. ncbi request reprint [Gynecological tumors during pregnancy]
    Tua Annanmaki
    Suomen Lääkätieteen Säätiö PL 713, 00101 Helsinki
    Duodecim 120:1085-90. 2004